Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.

Vanderbilt researchers propose that cellular signaling pathways are amplified by a “conveyor belt” mechanism that exchanges active and inactive enzymes.

DNA-binding “switches” represent a fundamentally new method of communication between DNA-processing enzymes, Vanderbilt researchers propose.

Craig Lindsley, PhD, a leader of Vanderbilt University School of Medicine’s groundbreaking drug discovery program, is being honored by the American Society for Pharmacology and Experimental Therapeutics (ASPET) for his transformative approaches to identifying potential new drugs.

Craig Lindsley, PhD, co-director of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD), has been named a fellow of the National Academy of Inventors (NAI).